2.62
-0.14 (-5.07%)
| Penutupan Terdahulu | 2.76 |
| Buka | 2.75 |
| Jumlah Dagangan | 2,055,159 |
| Purata Dagangan (3B) | 1,705,681 |
| Modal Pasaran | 257,759,104 |
| Harga / Jualan (P/S) | 0.510 |
| Harga / Buku (P/B) | 0.760 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Mar 2026 |
| Margin Keuntungan | -15.96% |
| Margin Operasi (TTM) | -9.49% |
| EPS Cair (TTM) | -0.700 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 10.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2,020.06% |
| Nisbah Semasa (MRQ) | 1.79 |
| Aliran Tunai Operasi (OCF TTM) | -15.64 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 5.58 M |
| Pulangan Atas Aset (ROA TTM) | -17.66% |
| Pulangan Atas Ekuiti (ROE TTM) | -277.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Care Facilities (US) | Menaik | Bercampur |
| Medical Care Facilities (Global) | Menaik | Menaik | |
| Stok | The Oncology Institute, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -3.5 |
| Purata | 0.00 |
|
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services. |
|
| Sektor | Healthcare |
| Industri | Medical Care Facilities |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 9.22% |
| % Dimiliki oleh Institusi | 34.63% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Josh Arnold Investment Consultant, Llc | 31 Dec 2025 | 2,459,809 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 7.00 (BTIG, 167.18%) | Beli |
| Median | 6.00 (129.01%) | |
| Rendah | 5.00 (Needham, 90.84%) | Beli |
| Purata | 6.00 (129.01%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 2.73 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 09 Mar 2026 | 7.00 (167.18%) | Beli | 2.73 |
| Needham | 09 Mar 2026 | 5.00 (90.84%) | Beli | 2.73 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Jan 2026 | Pengumuman | The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook |
| 09 Jan 2026 | Pengumuman | The Oncology Institute Announces Leadership Promotions |
| 05 Jan 2026 | Pengumuman | The Oncology Institute Announces Addition of Board Member Mark Stolper |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |